Solvuu

???????? ???????????? ???? ?????? ???????? ???? ??????????????????! Solvuu will be at the AMP2024 Annual Meeting & Expo in Vancouver from Nov 19-23. If you are at AMP2024 and interested in implementing ???? ???????????? RMs for your NGS assay or have clinical bioinformatics needs, please get in touch with Ashish Agarwal (CEO) or Raj Sasidharan (CSO) and let’s discuss how we could help you. We will be at the AMP Reference Materials Forum on Tuesday, Nov 19 where our advisor Birgit Funke, PhD, FACMG is giving a talk. #AMP2024 #AMPath24 #Solvuu #ReferenceMaterial #ClinicalBioinformatics #Diagnostics #InSilicoRMs #Oncology #NGS #AssayValidation https://amp24.amp.org/

We are excited to participate and deliver a lightning pitch at BioNJ’s ‘AI & Digital Health Day 2024’ on Monday, November 18, 2024 at the Stevens Institute of Technology in Hoboken. We look forward to connecting with the AI and digital health community at BioNJ!

???????????? ?????? ???????? ???????????????? ???? ?????????????????????? ???? ?????? ?????????????? ???????????????? ???????? ??????????????! We are thrilled to announce that Solvuu will be part of the 2024-2025 Digital Health cohort of the Endless Frontier Labs (EFL) program run by the NYU Stern School of Business! Our application was selected from 1,600 founding teams who applied from over 78 countries worldwide. We are honored to have been admitted to this incredible 9-month program and can’t wait to participate and learn from the EFL mentors and fellow entrepreneurs. Thank you to everyone on the EFL team, our partners, and, of course, to everyone on our team who works tirelessly to advance our mission!

???????? ???????????? ???? ?????? ?????????????? ???????? ?????????????? ?????????????????????? ???? ??????????????????????????! On Sep 18th, Ashish Agarwal, Solvuu's Founder and CEO will join Adi Wallach from CalmiGo Neurotech and Mousa Ahmadi, PhD from Laronix for a panel discussion on leveraging a commercial plan for attracting partners and investors. This masterclass will equip participants with skills on how to build fundable commercial plans to optimize their ventures' value. Reach out and connect with Ashish Agarwal to learn more about Solvuu! To learn more ??

???????? ???????????? ???? ???????????????? ????????! We are excited to participate at the BioTechX USA 2024. On Sep 17th at 3:30PM, Rafail Tasakis, PhD, Solvuu's Head of Business Development, will join Eziah Syed (CEO, mend?) and Archis B. (CEO, PyrOjas) for a panel discussion moderated by Dr. Glennis Mehra (Director of Biolabs@NYULangone). They will discuss ???????????????? ???????? ?????????? ???? ???????? ?????????????????????? ?????? ???????????????????? ????????????????; ?????????????????????????? ?????? ????????????????????. Attending #BioTechX this year? Connect with Rafail Tasakis, PhD to explore how Solvuu can help accelerate your bioinformatics/healthcare data analytics goals for therapeutics and diagnostics!

???????? ???????????? ???? ?????? ?????????????? ???????? ?????????????? ?????????????????????? ???? ??????????????????????????! On Sep 18th, Ashish Agarwal, Solvuu's Founder and CEO will join Adi Wallach from CalmiGo Neurotech and Mousa Ahmadi, PhD from Laronix for a panel discussion on leveraging a commercial plan for attracting partners and investors. This masterclass will equip participants with skills on how to build fundable commercial plans to optimize their ventures' value. Reach out and connect with Ashish Agarwal to learn more about Solvuu! To learn more ??

???????? ???????????? ???? ???????????????? ????????! We are excited to participate at the BioTechX USA 2024. On Sep 17th at 3:30PM, Rafail Tasakis, PhD, Solvuu's Head of Business Development, will join Eziah Syed (CEO, mend?) and Archis B. (CEO, PyrOjas) for a panel discussion moderated by Dr. Glennis Mehra (Director of Biolabs@NYULangone). They will discuss ???????????????? ???????? ?????????? ???? ???????? ?????????????????????? ?????? ???????????????????? ????????????????; ?????????????????????????? ?????? ????????????????????. Attending #BioTechX this year? Connect with Rafail Tasakis, PhD to explore how Solvuu can help accelerate your bioinformatics/healthcare data analytics goals for therapeutics and diagnostics!

????/????-???????????? ???????????????? '?????????????????? ????????' ???????????????? ?????????????? ???????????????? ?????? ???????????????????? ???????????????????????????? ???????????????? ?????????????? ??????????-?????????? ???????? ?????????????????????? A recent study published in ???????????? ???????????? [1] presents a 'proof-of-principle' Molecular Twin platform integrating molecular, histopathological, and clinical features from both healthy and tumor tissues. Utilizing machine learning-based multi-omic analysis, the platform predicts clinical outcomes in pancreatic ductal adenocarcinoma (PDAC). This approach reveals plasma proteins as highly predictive for disease-specific survival (DS), outperforming the carbohydrate antigen 19-9 (CA 19-9), which is the only FDA-approved diagnostic biomarker for PDAC. The Molecular Twin platform analyzed 6,363 clinical and multi-omic features from 74 patients in a pilot study. The multi-omic components consisted of DNA and RNA sequencing, proteomics, lipidomics, and pathology data to generate predictive models. The findings of the study were validated using four independent datasets, including PDAC samples from the TCGA cohort. However, the authors acknowledged limitations in validating previously published findings, likely due to small sample size and incomplete analyte sources. Regardless, this study showcases the promise of AI/ML-driven bioinformatics in cancer diagnosis and treatment. [1] https://hubs.ly/Q02L1HsX0

?????????????? ???????? ???????????????????? ?????? ???????????????? ?????? ???? ???? ???? ???????????????? Artificial Intelligence (AI) methods have swiftly made an impact in interactive data processing and analytics since the release of popular AI applications. But how can AI enhance translational bioinformatics when it comes to complex genomics data? In a recent article [1], the Genomics and Translational Bioinformatics Workgroup by AMIA (American Medical Informatics Association) has explored this topic on five levels: 1. ???????? ???????????????????????? ?????? ??????????????????????????: The cost of genome sequencing has dramatically decreased, resulting in an exponential increase in available sequencing data, which aids AI-driven genomic research and clinical diagnostics. However, despite several large repositories, the usability of genomic data remains limited due to siloed access, emphasizing the need for federated data-sharing architectures to enhance AI research and clinical applications. 2. ?????????????????? ?????????????? ???? ?????????????? ????????: Functional genomics benefits from resources like ClinVar and large-scale functional studies, such as the NIH's MorPhiC program, which enhance gene function knowledge and support AI applications with smaller datasets. Standardizing genomic data and integrating it into EHRs through efforts like GA4GH and HL7 FHIR are crucial for developing accurate AI models and enabling real-time clinical use of genomic data. 3. ?????????????? ?????? ???????????????????? ????????????????????????????: Researchers are shifting from using real patient data to artificially generated data and pretrained algorithms for AI training to address privacy concerns, especially with sensitive genomic information. Ensuring data accuracy from CLIA-certified labs and tackling bias through diverse data collection and bias correction algorithms are crucial for developing equitable and effective AI models in genomics. 4. ?????????????????????? ???????????????????? ?????? ??????????????????: Educating clinicians about AI/ML is critical to foster trust and appropriate use, ensuring they understand the benefits and limitations without overriding clinical judgment. Explainability, transparency, and interpretability of AI models are essential for adoption, requiring models to be understandable to clinicians, patients, and regulators through interpretable designs and explanation techniques. 5. ???????????????????? ????????????????????: The FDA’s current framework does not address adaptive AI, requiring additional clearance for significant changes to devices. Despite the 2021 SaMD Action Plan proposing a new regulatory framework for AI/ML technologies, no new framework has been developed yet, and recent FDA guidance suggests that models supporting physician judgment may be exempt from strict regulation, emphasizing the need to balance innovation and patient safety. [1] https://hub...

?????????????? ???????????????? ?????????????? ???? ?????? ?????????????????? ???? ?????????????????? ?????? ?????????????? ???????? Due to high levels of heterogeneity within and between different types of Idiopathic Inflammatory Myopathies (IIMs) there have been significant hurdles in diagnosis and medical care of affected patients. Improvements have been made thanks to Machine Learning (ML) methods in several aspects of comprehending IIMs, but the clinical utility of these have yet to be determined according to McLeish ???? ???? [1]. In this review, the authors present ML-driven advances in the following areas: - ??????????????????: Novel criteria have been described for diagnosing IMNM (Immune-Mediated Necrotising Myopathy) and IBM (Inclusion-Body Myositis) based on meta-analyses of previously known most effective features. - ???????????????? ??????????????: Association of myositis-associated antibodies (MSA) profiles with clinical features of IIMs has clarified patient stratification with regards to treatment options. - ?????????????????? ????????????????????????????: Immunophenotyping has become an established tool for biomarker discovery based on immune system cell behavior from different biological samples such as peripheral blood, muscles and other affected tissues. - ???????????????????? ????????????????: Advances of comprehensive understanding of IIMs have been empowered by integrating genomics, transcriptomics, proteomics, and metabolomics data. Significant discoveries include the identification of genetic biomarkers linked to the autophagy-lysosome pathway and muscle inflammation in IMNM. - ???????????????????? ???? ???????????????? ???? ?????????????????? ?????? ??????????????????????????: Thanks to supervised ML analyses relying on previous data points from both treatment responses and comorbidities of patients, healthcare professionals can now predict risks in disease outcomes and manifestations. - ?????????????? ??????????????: Deep learning ML methods have become crucial in image analysis of IIMs biopsies. By replacing human-made analysis there have been significant advances towards precision and sensitivity of imaging technologies. [1] https://hubs.ly/Q02Jtnj80